Huang Shuying, Qing Cheng, Huang Zikun, Zhu Yuanfang
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
Intensive Care Unit, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
Diagn Pathol. 2016 Jun 10;11(1):49. doi: 10.1186/s13000-016-0499-x.
Ovarian cancer is a malignant tumor with a poor prognosis. Accumulating evidence demonstrates that long non-coding RNAs (lncRNAs) are emerging regulators in cancer biology, and can be used as potential biomarkers for cancer diagnosis, prognosis and targeted therapy. The lncRNA CCAT2 (colon cancer associated transcript 2) was recently shown to be involved in several cancers; however, its role in ovarian cancer remains unknown.
Expression levels of the lncRNA CCAT2 in ovarian cancer tissues, adjacent normal tissues, and cell lines were assessed by quantitative real-time PCR. Then, the associations of CCAT2 expression levels with clinicopathological features and prognosis were evaluated. In addition, CCAT2 functions in tumor progression and invasion were further determined by siRNA-induced CCAT2 silencing in vitro.
Expression levels of the lncRNA CCAT2 in ovarian cancer tissues and cell lines were significantly higher compared with values obtained for adjacent non-tumor tissues and normal ovarian epithelial cells. Interestingly, higher CCAT2 expression levels were associated with a shorter overall survival (P = 0.006) and disease-free survival (P = 0.001) in ovarian cancer patients. In addition, CCAT2 expression was positively correlated with FIGO stage (P = 0.002), tumor grade (P = 0.006) and distant metastasis (P < 0.001). Moreover, CCAT2 knockdown in ovarian cancer cells markedly suppressed cell proliferation, migration, and invasion.
The lncRNA CCAT2 is a novel factor involved in ovarian cancer progression, and constitutes a potential prognostic biomarker and therapeutic target for patients with ovarian cancer.
卵巢癌是一种预后较差的恶性肿瘤。越来越多的证据表明，长链非编码RNA（lncRNA）在癌症生物学中逐渐成为调控因子，并且可作为癌症诊断、预后及靶向治疗的潜在生物标志物。最近研究表明，lncRNA CCAT2（结肠癌相关转录本2）与多种癌症相关；然而，其在卵巢癌中的作用尚不清楚。
通过定量实时PCR评估lncRNA CCAT2在卵巢癌组织、癌旁正常组织及细胞系中的表达水平。然后，评估CCAT2表达水平与临床病理特征及预后的相关性。此外，通过体外siRNA诱导CCAT2沉默进一步确定CCAT2在肿瘤进展和侵袭中的作用。
与癌旁非肿瘤组织和正常卵巢上皮细胞相比，lncRNA CCAT2在卵巢癌组织和细胞系中的表达水平显著更高。有趣的是，卵巢癌患者中CCAT2表达水平较高与总生存期较短（P = 0.006）和无病生存期较短（P = 0.001）相关。此外，CCAT2表达与国际妇产科联盟（FIGO）分期（P = 0.002）、肿瘤分级（P = 0.006）及远处转移（P < 0.001）呈正相关。而且，卵巢癌细胞中CCAT2敲低显著抑制细胞增殖、迁移及侵袭。
lncRNA CCAT2是参与卵巢癌进展的一个新因子，是卵巢癌患者潜在的预后生物标志物和治疗靶点。
